<DOC>
	<DOCNO>NCT00678405</DOCNO>
	<brief_summary>The aim study evaluate impact Breathlessness Intervention Service ( BIS ) quality life patient family affect intractable breathlessness . The question address research : 1 . Is BIS effective standard care patient intractable breathlessness advance malignant non-malignant disease ? 2 . Does reduce patient carer distress due breathlessness , increase patient ' sense mastery symptom ? 3 . What experience view use BIS , informal carers clinician refer ? 4 . Does BIS offer value money NHS ?</brief_summary>
	<brief_title>Trial Breathlessness Intervention Service Intractable Breathlessness</brief_title>
	<detailed_description>Research question : 1 . Is BIS effective standard care patient intractable breathlessness advance malignant non-malignant disease ? 2 . Does reduce patient &amp; carer distress due breathlessness , &amp; increase patient ' sense mastery symptom ? 3 . What experience &amp; view use BIS , informal carers &amp; clinician refer ? 4 . Is BIS cost-effective ? To assess change patient outcome attributable BIS , pragmatic RCT design conduct use fast-track design ( design prove highly acceptable Phase II ) . Analysis focus compare patient use BIS ( yet ) use BIS ( use BIS control group occur subsequent measurement point ) . The researcher blind allocation respondent discharge/referral BIS FT patient end wait period CC patient . This achieve researcher conduct study recruitment &amp; collect baseline measure instruct third party ( local clinical trial ' nurse ) conduct randomisation &amp; reporting allocation ( patient &amp; BIS ) use random sequence opaque envelop previously generate statistician independent BIS . Subsequently , data handle use study identity number ; group allocation identifier add analysis . This model use successfully Phase II pilot trial . Data collect control group receipt BIS ( period wait list group allocation blind researcher ) treat before/after data &amp; RCT data . This allow collection qualitative data group midpoint use BIS . The two broad disease course , malignant ( ) &amp; non-malignant ( nm ) , consider separately due different trajectory &amp; need , &amp; resultant different service model . The intervention model patient non-malignant disease consist two-three visit &amp; three telephone contact ( patient &amp; /or primary care staff ) four-week period 16 week ( first assessment ) follow , whereas model patient malignant disease consist one visit conjunction primary care professional/key worker &amp; two telephone contact ( patient &amp; /or primary care staff/key worker ) two-week period , six week ( first assessment ) follow . Thus , measurement point disease group differ . Data ( quantitative/qualitative ) collect respondent baseline ( t1 ) , prior randomisation . For non-malignant condition ( nm ) , repeat FT group ( nmFT ) midway intervention ( two week post commence BIS ; nmFTt2 - quantitative data ) &amp; equivalent time point CC group ( i.e . two week enter wait list ; nmCCt2 - quantitative data ) , discharge/referral BIS fast track group ( four week post commence BIS ; nmFTt3 ) &amp; four week discharge ( nmFTt5 ) . As well interview t1 ( randomisation ) &amp; t2 ( midway randomisation &amp; BIS - quantitative data ) , CC group ( nmCC ) also interview prior commence BIS ( nmCCt3 ) , BIS ( two week post commence BIS ; nmCCt4 ) &amp; discharge/referral BIS ( four week post commence BIS ( nmCCt5 ) . This allow identification whether respondent control group deteriorate significantly whilst wait BIS &amp; impact final outcome . This model successfully pilot Phase II . For malignant condition ( ) , baseline measure ( t1 ) repeat FT group ( mFT ) discharge/referral BIS ( two week post commencement BIS ; mFTt3 ) &amp; two week discharge ( mFTt5 ) . For CC group ( mCC ) baseline measure ( t1 ) repeat prior commence BIS ( mCCt3 ) &amp; discharge/referral BIS ( two week post commence BIS ; mCCt5 ) . Thus , due short time frame malignant service model , would t2 t4 measurement point . Sample size base exist literature &amp; experience Phase II . The estimated standard deviation primary outcome measure 2.5 . In order detect 2-point difference mean outcome group ( equivalent 0.8sd effect size ) 80 % power use t-test 5 % level significance , necessary recruit 26 patient per arm per disease group ( trial ) follow provide outcome , early time point minimize attrition . By adjust baseline primary outcome measure analysis use analysis covariance anticipate improvement precision estimate intervention effect . We also anticipate improvement use trial NRS measure rather highly variable VAS version pilot use sample size calculation . Therefore propose recruit 120 patient , 60 per disease group ensure adequate power , effect size allowance attrition . Analysis intention treat basis . Primary analysis analysis covariance NRS final time-point adjustment baseline NRS order improve precision estimate BIS versus comparison effect . Secondary analysis sensitively incorporate time-points repeat measure linear regression able detect difference BIS &amp; comparison emerging/changing time within initial period . All analysis document prior final data collection analysis plan , address two-tailed test &amp; assess 5 % level significance . Effects within &amp; arm summarize use mean &amp; 95 % confidence interval . If randomise effect similar malignant &amp; non-malignant group , combine effect estimate allow narrow overall confidence interval . Analysis conduct use SPSS software . The cost BIS patient calculate service activity data combine staff salary cost , plus on-costs , overhead &amp; equipment . Information use health &amp; social service &amp; informal care ( proxy-valued homecare worker ) collect Client Service Receipt Inventory . This combined appropriate unit cost data ( Curtis &amp; Netten , 2006 ) generate service cost . Cost comparison make use bootstrapping method account skewness data distribution . Cost-effectiveness assess combine cost data outcomes include quality-adjusted life year ( QALYS ) , form incremental cost-effectiveness ratio &amp; acceptability curve . Qualitative data analyse use framework approach ( Ritchie &amp; Spencer , 1993 ) conduct use NVivo software .</detailed_description>
	<mesh_term>Dyspnea</mesh_term>
	<criteria>Patient inclusion criterion : 1. appropriate referral BIS 2. age 18 years+ 3. patient meeting exclusion criterion . Carer inclusion criterion : 1. informal carers ( significant others , relative , friend neighbor ) Phase III RCT recruit 2. age 18 years+ 3. carer meeting exclusion criterion . 1. unable give inform consent 2. previously use BIS 3. demented/confused 4. learn difficulty 5. vulnerable group e.g . head injury , severe trauma , mental illness 6. meeting inclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Breathlessness</keyword>
	<keyword>Dyspnoea</keyword>
	<keyword>Dyspnea</keyword>
	<keyword>Palliative care</keyword>
	<keyword>RCT</keyword>
	<keyword>Randomised control trial</keyword>
	<keyword>Lung cancer</keyword>
	<keyword>COPD</keyword>
	<keyword>Heart failure</keyword>
	<keyword>Chronic respiratory disease</keyword>
</DOC>